Good
Mostly Aligned
Patient Risk:
Low
Summary
Most mechanism/PK and interaction concepts are consistent with the provided label excerpts (bile acid binding in intestine, fecal loss, fat-soluble vitamin absorption interference, and timing separation for other oral drugs). However, several cholesterol-related and tolerability statements are either generalized beyond the excerpted label or not directly supported with the same level of specificity, lowering overall alignment.
Category Scores
Accurate Statements
Cholestyramine belongs to the bile acid sequestrant drug class.
5 PRECAUTIONS/12 CLINICAL PHARMACOLOGY excerpts describe a resin that adsorbs bile acids in the intestine (mechanism consistent with bile acid sequestrant class).
Cholestyramine is used to bind bile acids in the gut.
12 CLINICAL PHARMACOLOGY: resin adsorbs and combines with bile acids in the intestine.
By binding bile acids in the gut, cholestyramine lowers bile acid availability.
12 CLINICAL PHARMACOLOGY: partial removal of bile acids from enterohepatic circulation.
Bile acid sequestrants work in the gastrointestinal tract by binding bile acids.
12 CLINICAL PHARMACOLOGY: bile acids in the intestine to form an insoluble complex excreted in feces.
Binding bile acids reduces bile acid reabsorption.
12 CLINICAL PHARMACOLOGY: partial removal of bile acids from enterohepatic circulation.
Binding bile acids increases bile acid loss through stool.
12 CLINICAL PHARMACOLOGY: increased fecal loss; excreted in feces.
Cholestyramine can affect the absorption of other oral medications.
7 DRUG INTERACTIONS: may delay or reduce absorption of concomitant oral medication; recommended timing separation.
Separating dosing times from other drugs may reduce the chance of reduced effectiveness.
7 DRUG INTERACTIONS: recommended take other drugs at least one hour before or 4 to 6 hours after QUESTRAN.
Because bile acid sequestrants act in the digestive tract, patients commonly ask about gastrointestinal tolerance.
Supported only indirectly by the label listing constipation/GI adverse reactions; the 'commonly ask' phrasing is not explicitly in the provided excerpts.
Cholestyramine targets bile acids by binding them in the digestive tract.
12 CLINICAL PHARMACOLOGY: adsorbs and combines with bile acids in the intestine.
Unsupported Statements
Lower bile acid availability helps reduce cholesterol levels.
The label excerpts support decreased serum cholesterol/LDL via bile acid removal, but the provided excerpts do not explicitly state this causal phrasing 'Lower bile acid availability helps reduce cholesterol levels.'
Lower bile acid availability helps reduce cholesterol levels.
Mechanism is described (increased fecal loss leads to decreased LDL and serum cholesterol), but the exact 'bile acid availability' framing is not explicit in the excerpt.
Increased bile acid loss through stool can shift the body toward using cholesterol to make new bile acids.
Not supported in the provided label excerpts.
Cholestyramine is used for elevated cholesterol as part of lipid-lowering therapy.
The provided label excerpts describe indications for reduction of elevated serum cholesterol/LDL as adjunctive therapy to diet; however, the statement is generalized and not mapped to the exact 'adjunctive therapy to diet' wording in the provided text.
Cholestyramine is not a statin.
No explicit statement in the provided label excerpts addressing whether it is or is not a statin.
Cholestyramine does not lower cholesterol by directly inhibiting cholesterol synthesis.
No explicit statement in the provided label excerpts about cholesterol synthesis inhibition.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
No label-captured dosing/administration details were provided in the AI statements (e.g., mix with water/other fluids; dosing frequency; timing with food).
Importance:
Moderate
No mention of key contraindication(s) (e.g., complete biliary obstruction; hypersensitivity) despite being a common safety-critical topic.
Importance:
Moderate
No mention of the specific adverse reaction 'constipation' or other listed GI adverse reactions, beyond a generalized 'gastrointestinal tolerance' statement.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Statements largely reflect the label mechanism and interaction timing concept. Potential risk comes from several unsupported/generalized claims (statin denial and cholesterol synthesis mechanism) and an unlabelled claim about physiology (using cholesterol to make new bile acids).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several cholesterol-related explanations are not supported verbatim by the provided label excerpts, and statin/synthesis claims are absent from the label excerpts.
Suggested Improvement
Replace generalized/non-explicit mechanistic statements with label-supported phrasing (e.g., resin adsorbs bile acids in the intestine, forms insoluble complex excreted in feces, decreased LDL/serum cholesterol). Omit 'not a statin' and 'does not inhibit cholesterol synthesis' unless the label excerpt explicitly states these.